




The relative strengths and weaknesses of Juniper Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Juniper Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 119% points. The greatest weakness of Juniper Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 424%, being 204% points above the market average of 220%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	35,972	Assets	36,938
Cost of Goods Sold	12,788	Liabilities	5,022
Intangible Assets	0	Expenses	23,022
Liabilities, Current	3,815	Revenues	25,828
Liabilities, Non-Current	0	Stockholders Equity	31,915
Other Assets	39	Net Income	9,917
Other Compr. Net Income	0	Comprehensive Net Income	9,917
Other Expenses	893	BaseVar	48,960
Other Liabilities	1,207	ECR before LimitedLiability	379%
Other Net Income	7,110	Economic Capital Ratio	424%
Other Revenues	25,828		
Property and Equipment	927		
Research and Development	771		
Selling, General and Administrative Expense	8,570		